Regression of radiation-induced macular edema after systemic bevacizumab.
METHODS
A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer. Eight months following EBR, he showed evidence of radiation retinopathy with macular edema. Optical coherence tomography (OCT) showed macular edema and subretinal fluid. Subsequently, systemic bevacizumab (5 mg/kg) was added to his leukovorin/5FU chemotherapy. After the addition of bevacizumab, OCT showed complete resolution of the macular edema and subretinal fluid.


CONCLUSIONS
Bevacizumab may have a role in the treatment of radiation retinopathy, but further investigation is needed before any definitive conclusions can be made.
Solano
Joel M
JM
Mayo Clinic, Rochester, MN 55905, USA.
Bakri
Sophie J
SJ
Pulido
Jose S
JS
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000068258:Bevacizumab; D002830:Choroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000532:radiotherapy*; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D011832:Radiation Injuries / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A; D014803:Vitamin B Complex / Q000627:therapeutic use